Erasca, Inc. (ERAS)

NMS – Real Time Price. Currency in USD

10.38

-0.06 (-0.57%)

At close: May 12, 2026, 4:00 PM EDT

10.42

+0.04 (0.39%)

After-hours: May 12, 2026, 7:49 PM EDT

11.05.2026

Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks

I initiate Erasca (ERAS) with a "Hold" rating due to promising phase 1 ERAS-0015 data but significant risks. ERAS-0015 showed high ORR in KRAS-mutant NSCLC [64%] and PDAC [50%] at RDE but faces safety and patent litigation risks. Company has strong cash reserves, global rights to ERAS-0015, and a Merck supply collaboration agreement for combination trials.

11.05.2026

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents

11.05.2026

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab

10.05.2026

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or “the Company”) (NASDAQ: ERAS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

07.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

06.05.2026

Erasca to Present at the Bank of America Securities Health Care Conference

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2026 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 pm Pacific Time and will also participate in one-on-one investor meetings.

04.05.2026

Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation

Investors who lost money in Erasca Inc. (Nasdaq: $ERAS) should contact Block & Leviton to potentially recover losses via securities fraud investigation.

Videos

No Data

There is no data to display

Press releases

11.05.2026

Erasca Reports First Quarter 2026 Business Updates and Financial Results

11.05.2026

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

10.05.2026

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

07.05.2026

Erasca, Inc. (ERAS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Erasca, Inc. (ERAS)

Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation

Videos

No Data

Press releases

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation

Videos

No Data

Press releases

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Search stocks

Erasca, Inc. (ERAS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Erasca, Inc. (ERAS)

Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation

Videos

No Data

Press releases

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation

Videos

No Data

Press releases

Erasca Reports First Quarter 2026 Business Updates and Financial Results

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS